Phaseline

Targets › SLC6A19

SLC6A19 (Sodium-dependent neutral amino acid transporter B(0)AT1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.

Transporter that mediates resorption of neutral amino acids across the apical membrane of renal and intestinal epithelial cells. This uptake is sodium-dependent and chloride-independent. (UniProt, Q695T7)

Open in Phaseline: the race on SLC6A19, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Changchun GeneScience PharmaceuticalGenSci144 tablets
SLC6A19 transporter small molecule inhibitor
SLC6A19Phase 1PhenylketonuriaDec 2026

Conditions

Phenylketonuria (1)

Modalities

small molecule (1)

Companies

Changchun GeneScience Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.